Improving IBD outcomes in the era of many treatment options

Key studies published in 2022 highlight the emergence of several novel drugs for inflammatory bowel disease. Head-to-head trials and network meta-analyses have also been conducted to identify the sequencing of these treatments, but we still have a long way to go to achieve personalized medicine.

Detalles Bibliográficos
Autores principales: Kobayashi, Taku, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Year in Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838431/
https://www.ncbi.nlm.nih.gov/pubmed/36635556
http://dx.doi.org/10.1038/s41575-022-00738-z
_version_ 1784869284902600704
author Kobayashi, Taku
Hibi, Toshifumi
author_facet Kobayashi, Taku
Hibi, Toshifumi
author_sort Kobayashi, Taku
collection PubMed
description Key studies published in 2022 highlight the emergence of several novel drugs for inflammatory bowel disease. Head-to-head trials and network meta-analyses have also been conducted to identify the sequencing of these treatments, but we still have a long way to go to achieve personalized medicine.
format Online
Article
Text
id pubmed-9838431
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98384312023-01-17 Improving IBD outcomes in the era of many treatment options Kobayashi, Taku Hibi, Toshifumi Nat Rev Gastroenterol Hepatol Year in Review Key studies published in 2022 highlight the emergence of several novel drugs for inflammatory bowel disease. Head-to-head trials and network meta-analyses have also been conducted to identify the sequencing of these treatments, but we still have a long way to go to achieve personalized medicine. Nature Publishing Group UK 2023-01-12 2023 /pmc/articles/PMC9838431/ /pubmed/36635556 http://dx.doi.org/10.1038/s41575-022-00738-z Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Year in Review
Kobayashi, Taku
Hibi, Toshifumi
Improving IBD outcomes in the era of many treatment options
title Improving IBD outcomes in the era of many treatment options
title_full Improving IBD outcomes in the era of many treatment options
title_fullStr Improving IBD outcomes in the era of many treatment options
title_full_unstemmed Improving IBD outcomes in the era of many treatment options
title_short Improving IBD outcomes in the era of many treatment options
title_sort improving ibd outcomes in the era of many treatment options
topic Year in Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838431/
https://www.ncbi.nlm.nih.gov/pubmed/36635556
http://dx.doi.org/10.1038/s41575-022-00738-z
work_keys_str_mv AT kobayashitaku improvingibdoutcomesintheeraofmanytreatmentoptions
AT hibitoshifumi improvingibdoutcomesintheeraofmanytreatmentoptions

Ejemplares similares